Treatment with semaglutide and other GLP-1 analogues is often associated with improvements in serum aminotransferase levels [7], making them potential treatments for non-alcoholic fatty liver disease. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.